Pricing
  1. US-listed companies
  2. HALOZYME THERAPEUTICS, INC.
  3. Financials
  4. Cash from investing

HALOZYME THERAPEUTICS, INC. (HALO)

Market cap
$7.9B
P/E ratio
SummaryFinancials
Period EndCash from investing (Million USD)YoY (%)
Dec 31, 2024-263+171.10%
Dec 31, 2023-97-80.10%
Dec 31, 2022-487+19.87%
Dec 31, 2021-406-618.53%
Dec 31, 202078-1512.04%
Dec 31, 2019-6-322.58%
Dec 31, 20182-101.52%
Dec 31, 2017-164+113.29%
Dec 31, 2016-77-1403.77%
Dec 31, 20156-117.87%
Dec 31, 2014-33-31.16%
Dec 31, 2013-48+3288.76%
Dec 31, 2012-1+70.50%
Dec 31, 2011-1

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat